Zusammenfassung
Ziel adjuvanter chemotherapeutischer Behandlungsmaßnahmen ist die Eradikation verborgener lymphogener und insbesondere hämatogener Mikrometastasen, die sich nach der Entfernung des Primärtumors und der axillären Lymphknoten noch im Organismus befinden können. Nachbeobachtungen von Patientinnen, die vor 20 Jahren adjuvant medikamentös behandelt worden waren, zeigen, daß etwa 5 bis 8% aller Frauen durch die systemische Therapie zusätzlich geheilt werden können, was einer Senkung der zu erwartenden Mortalität um 15–25% entspricht. Die Heilungsquote liegt um so höher, je geringer die primäre Tumorausdehnung ist. Vielversprechend sind zusätzliche Therapieverfahren, wie die Gabe von Bisphosphonaten, von Antikörpern, die gegen Tumorzellen, Wachstumsfaktor-Rezeptoren oder Onkogenprodukte gerichtet sind, oder in Zukunft vielleicht von Medikamenten, die die Tumorangiogenese unterdrücken.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 332(14): 901–906.
Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273(7): 542–547.
Crump M, Goss PE, Prince M, Girouard C (1996) Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 14(1): 66–69.
Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group (1996) Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 88(24): 1834–1839.
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomies trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: 1–5, 71–85.
Early Breast Cancer Trialists’ Collaborative Group (1996) Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 348(9036): 1189–1196.
Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21): 1529–1542.
Fisher B, Brown AM, Mamounas E, Wiand S, Robidoux A, Margolese RG, Cruz AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from national surgical adjuvant breast and bowel project B18. J Clin Oncol 15(7): 2483–2493.
Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, Wolmark N, Pugh R, Atkins JN, Meyers FJ, Abramson N, Wolter J, Bornstein RS, Levy L, Romond EH, Caggiano V, Grimaldi M, Jochimsen P, Deckers P (1997) Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15(5): 1858–1869.
Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Dimitrov N, Abraham N, Atkins JN, Shibata H, Deschenes L, Margolese RG (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89(22): 1673–1682.
Gianni AM, Siena S, Bregni M, Di-Nicola M, Orefice S, Cusumano F, Salvadori B, Luini A, Greco M, Zucali R, Rilke F, Zambetti M, Valagussa P, Bonadonna G (1997) J Clin Oncol 15(6): 2312–2321.
Hortobagyi GN, Buzdar AU (1995) Current status of adjuvant systemic therapy for primary breast cancer: Progress and controversy. CA Cancer J Clin 45(4): 199–226.
Peters WP (1995) High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: Yes. Important-Adv-Oncol: 215–230.
Peters WP (1995) High-dose chemotherapy as adjuvant therapy for breast cancer: Where do we stand? 5th International Conference on Adjuvant Therapy of Primary Breast Cancer, St. Gallen, March 1–4, Abstract 19.
Pritchard KI, Paterson AH, Fine S, Paul NA, Zee B, Shepherd LE, Abu-Zahra H, Ragaz J, Knowling M, Levine MN, Verma S, Perrault D, Walde PL, Bramwell VH, Poljicak M, Boyd N, Warr D, Norris BD, Bowman D, Armitage GR, Weizel H, Buckman RA (1997) Randomized trial of cyclophosphamide, methotrexate, and flu-orouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J Clin Oncol 15(6): 2302–2311.
Ragaz J, Jackson SM, Le N, Plenderleith IH, Wilson K, Knowling M, Olivotto I, Basco V, Spinelli J, Coldman A (1997) Can ovarian ablation improve outcome of stage I-II premenopausal breast cancer patients with estrogen receptor positive tumors treated with adjuvant chemotherapy? Long term analysis of British Columbia randomized trial. Proc of ASCO (16), S. 142a, Abstract 501.
Rutges P (1997) Breast Cancer Conference, Amsterdam, PP-5-1.
Swedish Breast Cancer Cooperative Group (1996) Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88(21): 1543–1549.
Zambetti M, Valagussa P, Bonadonna G (1996) Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Updated results. Ann Oncol 7(5): 481–485.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Wien
About this chapter
Cite this chapter
Possinger, K., Große, Y., Senn, HJ. (1999). Adjuvante Behandlung des primären Mammacarcinoms. In: Zielinski, C., Jakesz, R. (eds) Mammacarcinom. Onkologie heute. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6402-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6402-0_5
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83168-7
Online ISBN: 978-3-7091-6402-0
eBook Packages: Springer Book Archive